UBS Group
GSK icon

UBS Group’s GSK GSK Stock Holding History

UBS Group’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Buy
55,200
+5,200
+10% +$275K ﹤0.01% 4742
2026
Q1 		$2.76M Buy
+50,000
New +$2.71M ﹤0.01% 4673
2025
Q4 		– Sell
-50,000
Closed -$2.16M – 10773
2025
Q3 		$2.16M Buy
+50,000
New +$1.95M ﹤0.01% 4875
2025
Q2 		– Sell
-30,000
Closed -$1.16M – 10487
2025
Q1 		$1.16M Sell
30,000
-237,700
-89% -$8.7M ﹤0.01% 5157
2024
Q4 		$9.05M Buy
267,700
+42,800
+19% +$1.54M ﹤0.01% 3168
2024
Q3 		$9.19M Buy
+224,900
New +$9.2M ﹤0.01% 2451
2024
Q1 		– Sell
-24,000
Closed -$889K – 9595
2023
Q4 		$889K Buy
+24,000
New +$862K ﹤0.01% 4604
2023
Q3 		– Sell
-52,700
Closed -$1.88M – 9651
2023
Q2 		$1.88M Hold
52,700
– – ﹤0.01% 3591
2023
Q1 		$1.88M Sell
52,700
-62,300
-54% -$2.18M ﹤0.01% 3504
2022
Q4 		$4.04M Buy
+115,000
New +$3.83M ﹤0.01% 2702
2022
Q2 		– Sell
-240
Closed -$13K – 10558
2022
Q1 		$13K Buy
+240
New +$13K ﹤0.01% 8047
2021
Q4 		– Sell
-72,800
Closed -$3.48M – 10425
2021
Q3 		$3.48M Buy
+72,800
New +$3.66M ﹤0.01% 3064
2016
Q4 		– Sell
-400
Closed -$22K – 7867
2016
Q3 		$22K Buy
+400
New +$21.9K ﹤0.01% 6220
2016
Q1 		– Sell
-1,920
Closed -$97K – 7841
2015
Q4 		$97K Hold
1,920
– – ﹤0.01% 5238
2015
Q3 		$92K Sell
1,920
-81,200
-98% -$4.23M ﹤0.01% 5299
2015
Q2 		$4.33M Sell
83,120
-3,200
-4% -$180K ﹤0.01% 2221
2015
Q1 		$4.98M Buy
86,320
+77,840
+918% +$4.46M ﹤0.01% 2074
2014
Q4 		$453K Buy
+8,480
New +$474K ﹤0.01% 4290

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

UBS Group's GSK Position: Q2 2026 in Review

UBS Group increased its GSK (GSK) stake by 35% in Q2 2026, buying an estimated $38.2M and bringing the position to 2,806,205 shares worth $147M. The position accounts for 0.02% of the portfolio, ranked #864.

UBS Group first reported a position in GSK in Q4 2014 and has held it in 47 quarters since. The position peaked at $308M in Q4 2025. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • UBS Group held 2,806,205 shares of GSK worth $147M as of Q2 2026.
  • UBS Group bought 721,970 GSK shares in Q2 2026, an estimated $38.2M.
  • GSK made up 0.02% of UBS Group's portfolio in Q2 2026, its #864 holding.
  • UBS Group first reported a position in GSK in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's GSK position peaked at $308M in Q4 2025.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.